Long-term use of XXXX in liver grafting.

@entity1 @entity101 @entity500 @entity205 @entity1011 @entity10 @entity551 @entity617 @entity288
The clinical course of 29 liver graft recipients in the Cambridge/King's College Hospital series who have received @entity205 (CyA) for up to five years (median 40 months) was analysed with particular reference to the immunosuppressive effectiveness and adverse effects of the drug. Eight @entity1 had been maintained on @entity617 and @entity500 for two to six years before treatment was changed to @entity205 and the remainder were started on @entity205 after operation. Results in both groups over a one to five year study period are similar, and showed that @entity205 was effective in maintaining adequate immunosuppression, allowing complete withdrawal of prednisolone in 16 @entity1 . Episodes of rejection were observed in only three @entity1 and in two of these it was of the chronic 'vanishing bile duct' variety. Some evidence of nephrotoxicity (serum @entity1011 greater than 150 mumol/l) occurred in 72 per cent (21 of 29 @entity1 ) but it was necessary to discontinue treatment in only two. @entity101 , occasionally of sudden onset, was found in nine @entity1 and led to the withdrawal of the drug in two. Additional @entity551 drug treatment was required in five. In one other @entity1 @entity205 was discontinued on account of severe @entity10 . @entity205 was withdrawn in two further @entity1 . Withdrawal led to considerable risk of acute rejection and increased doses of @entity288 as well as substitution of @entity500 were required at that time.
